Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 13, 2019 16:15 ET | Source: Altimmune, Inc.

Altimmune Announces Third Quarter 2019 Financial Results and Provides a Business Update

GAITHERSBURG, Md., Nov. 13, 2019 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced financial results for the quarter ended September 30,...
November 06, 2019 07:00 ET | Source: Altimmune, Inc.

Altimmune to Announce Third Quarter 2019 Financial Results on November 14

GAITHERSBURG, Md., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical stage biopharmaceutical company focused on developing liver disease and immune modulating therapies,...
October 10, 2019 07:00 ET | Source: Altimmune, Inc.

Altimmune to Participate in Upcoming Investor Conferences

GAITHERSBURG, Md., Oct. 10, 2019 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that management will participate in the following...
September 09, 2019 07:00 ET | Source: Altimmune, Inc.

Altimmune Appoints M. Scott Harris, M.D. as Chief Medical Officer

GAITHERSBURG, Md., Sept. 09, 2019 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced it has appointed M. Scott Harris, M.D. as Chief...
August 21, 2019 07:00 ET | Source: Altimmune, Inc.

Altimmune Announces $3.7 Million in Additional BARDA Funding to Advance NasoShield™ Clinical Development

GAITHERSBURG, Md., Aug. 21, 2019 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that the Biomedical Advanced Research and Development...
August 13, 2019 16:15 ET | Source: Altimmune, Inc.

Altimmune Announces Second Quarter 2019 Financial Results and Provides a Business Update

GAITHERSBURG, Md., Aug. 13, 2019 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced financial results for the three and six months ended...
August 05, 2019 07:00 ET | Source: Altimmune, Inc.

Altimmune to Announce Second Quarter 2019 Financial Results on August 14

GAITHERSBURG, Md., Aug. 05, 2019 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical stage biopharmaceutical company focused on developing liver disease and immune modulating therapies,...
July 15, 2019 07:00 ET | Source: Altimmune, Inc.

Altimmune Announces Closing of Acquisition of Spitfire Pharma, Inc.

GAITHERSBURG, Md., July 15, 2019 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced the closing of the previously announced acquisition of...
July 09, 2019 07:00 ET | Source: Altimmune, Inc.

Altimmune Signs Definitive Agreement to Acquire Spitfire Pharma, Inc. Adding NASH Drug Candidate to Portfolio

Company to receive rights to novel GLP-1/glucagon dual agonist that addresses obesity and metabolic dysfunction, primary causes of NASH Greater impact on liver fat, inflammation and fibrosis compared...
June 12, 2019 08:00 ET | Source: Altimmune, Inc.

Altimmune Appoints Will Brown as Chief Financial Officer

GAITHERSBURG, Md., June 12, 2019 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced it has appointed Will Brown as Chief Financial...